Compare Intel Corp (INTC) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intel Corp vs 10X Genomics Inc — how do they compare? Intel Corp trades at $104.26 (market cap $487.82B), while 10X Genomics Inc trades at $45.71 (market cap $5.48B). The key difference: Intel Corp is far larger — about 89× 10X Genomics Inc's market cap, and Intel Corp pays a 2.24% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| INTC | TXG | |
|---|---|---|
Market Cap | $487.82B | $5.48B |
Volume | 43,552,012 | — |
Sector | Technology | Health |
52-Week High | $140.94 | $45.80 |
52-Week Low | $19.31 | $11.34 |
Enterprise Value | $500.07B | $5.02B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $97.87, up 2.97% on the day, with technical indicators showing a bullish overall signal despite mixed moving averages. The company has beaten earnings estimates for three consecutive quarters, though it reported a net loss of -$267 million in 2025. Recent news highlights volatility in semiconductor stocks amid AI-driven market shifts, with Intel expanding its Google Cloud AI partnership to boost enterprise growth.
Intel's outlook is cautiously optimistic, supported by earnings beats and strategic AI initiatives, but risks include intense competition, margin pressures, and sector volatility. The consensus price target of $109.55 suggests potential upside, though investors must weigh financial recovery against technological challenges in a dynamic chip market.
TXG trades at $43.18, down 1.28% today, with a bullish technical signal and positive earnings momentum. The stock shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while maintaining a strong gross margin of 69.6%. Recent acquisitions and partnerships with Cleveland Clinic demonstrate strategic expansion in genomic diagnostics.
The outlook remains cautiously optimistic with analyst consensus at Buy (45%) and price target of $39.14. Key risks include continued negative profitability metrics and high valuation multiples, while catalysts include upcoming Q2 2026 earnings and platform adoption growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
